You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 300 No. 9, September 3, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Clinical Crossroads: Conferences With Patients and Doctors
 This Article
 •Full text
 •PDF
 •Correction
 •CME Course for This Article
 • Submit Response to Patient's Crossroads
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 • Readers Responses
 •Similar articles in JAMA
 Topic Collections
 •HIV/AIDS
 •Nutritional and Metabolic Disorders
 •Nutritional and Metabolic Disorders, Other
 •Patient-Physician Relationship/ Care
 •Psychosocial Issues
 •Quality of Life
 •Drug Therapy
 •Adverse Effects
 •Facial Plastic Surgery
 •Facial Plastic Surgery, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

CLINICIAN'S CORNER
A 39-Year-Old Man With HIV-Associated Lipodystrophy

Jon Fuller, MD, Discussant

JAMA. 2008;300(9):1056-1066.

Human immunodeficiency virus (HIV)–associated lipodystrophy refers to fat accumulation, also known as lipohypertrophy, and fat wasting, also known as lipoatrophy. Both conditions can be very disturbing to patients and have been associated with metabolic disturbances such as insulin resistance and hyperlipidemias. The prevalence of HIV-associated lipodystrophy ranges from 6% to 69% in the medical literature. Although no clear associations have been made between specific drugs and HIV lipohypertrophy, stavudine and zidovudine have been implicated in the development of HIV lipoatrophy. The case of Mr B, a 39-year-old man with HIV-associated lipodystrophy whose facial changes are a cause of significant distress, highlights the need for clinicians to be attuned to the psychological impact that lipodystrophy can have on patients, especially because it may serve as a disincentive to adherence to antiretroviral drug regimens, resulting in an increased risk of developing viral resistance.


Author Affiliation: Dr Fuller is Associate Professor, Boston University School of Medicine, and Staff Member, Center for HIV/AIDS Care and Research, Boston Medical Center, Boston, Massachusetts.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?




RAPID RESPONSES TO THIS ARTICLE

Lipodystrophy: A Disease of Diseases
Daniel M Riche
JAMA Online, 4 Sep 2008.
TEXT 



HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.